Navigation Links
Quintessence Secures Financing

MADISON, WI. - Quintessence Biosciences, Inc., a biotechnology company developing pharmaceutical products for use in research, has finalized a three million dollar financing deal. The majority of the funding, $2.3 million, was received from individual investors, and the remainder was borrowed from the Madison Development Corporation, Wisconsin Department of Commerce, and m2 Lease Funds, a private ......

Full article >>> as received, it has been placed in the exciting position of entering the marketplace with highly sought new tools for protein research.

One of the projects of Quintessence Biosciences is the formulation of multivalent drugs. Multivalent drugs are a new class of medications able to attach to pathogens with several binding sites, enabling them to be precise enough tools to treat a wide va......

Full article >>> ged cartilage or ligaments. Also, collagen is also required for the healing of wounds; products using synthetic collagen could assist in wound treatment.

"Its worth noting that both Quintessence and Nutra-Park, which also announced a round of financing last Thursday, were presenters at the November 2002 Wisconsin Life Sciences Venture Conference sponsored by the Wisconsin Technology Coun......

Full article >>>
'"/>

Source:wistechnology.com By Jamie Lyn Hofmeister 05/28/03


Related biology technology :

1. Quintessence Biosciences advances cancer drug
2. Quintessence Biosciences names new president
3. Quintessence cancer treatment chosen for clinical studies
4. Quintessence division to develop drug tests with NIH grant
5. Quintessence Biosciences forms cancer therapeutic advisory board
6. nPoint Secures Second Round of Funding
7. Financing life science: The ongoing saga
8. Financing of biotech companies so far in 2005: A Midwest odyssey
9. Seed-Stage Venture Financing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):